177 related articles for article (PubMed ID: 26330531)
1. Metformin attenuates olanzapine-induced hepatic, but not peripheral insulin resistance.
Remington GJ; Teo C; Wilson V; Chintoh A; Guenette M; Ahsan Z; Giacca A; Hahn MK
J Endocrinol; 2015 Nov; 227(2):71-81. PubMed ID: 26330531
[TBL] [Abstract][Full Text] [Related]
2. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects.
Houseknecht KL; Robertson AS; Zavadoski W; Gibbs EM; Johnson DE; Rollema H
Neuropsychopharmacology; 2007 Feb; 32(2):289-97. PubMed ID: 17035934
[TBL] [Abstract][Full Text] [Related]
3. Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance.
Martins PJ; Haas M; Obici S
Diabetes; 2010 Oct; 59(10):2418-25. PubMed ID: 20682682
[TBL] [Abstract][Full Text] [Related]
4. Insulin resistance following continuous, chronic olanzapine treatment: an animal model.
Chintoh AF; Mann SW; Lam TK; Giacca A; Remington G
Schizophr Res; 2008 Sep; 104(1-3):23-30. PubMed ID: 18675538
[TBL] [Abstract][Full Text] [Related]
5. Metformin ameliorates olanzapine-induced insulin resistance via suppressing macrophage infiltration and inflammatory responses in rats.
Guo C; Liu J; Li H
Biomed Pharmacother; 2021 Jan; 133():110912. PubMed ID: 33217690
[TBL] [Abstract][Full Text] [Related]
6. Role of glucose-6 phosphatase, glucokinase, and glucose-6 phosphate in liver insulin resistance and its correction by metformin.
Minassian C; Tarpin S; Mithieux G
Biochem Pharmacol; 1998 Apr; 55(8):1213-9. PubMed ID: 9719475
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine-induced changes in glucose metabolism are independent of the melanin-concentrating hormone system.
Girault EM; Toonen PW; Eggels L; Foppen E; Ackermans MT; la Fleur SE; Fliers E; Kalsbeek A
Psychoneuroendocrinology; 2013 Nov; 38(11):2640-6. PubMed ID: 23856185
[TBL] [Abstract][Full Text] [Related]
8. Metabolic side-effects of the novel second-generation antipsychotic drugs asenapine and iloperidone: a comparison with olanzapine.
Boyda HN; Procyshyn RM; Pang CC; Hawkes E; Wong D; Jin CH; Honer WG; Barr AM
PLoS One; 2013; 8(1):e53459. PubMed ID: 23326434
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of 3 classes of antidiabetic drugs on olanzapine-induced glucose dysregulation and insulin resistance in female rats.
Boyda HN; Procyshyn RM; Tse L; Hawkes E; Jin CH; Pang CC; Honer WG; Barr AM
J Psychiatry Neurosci; 2012 Nov; 37(6):407-15. PubMed ID: 22640703
[TBL] [Abstract][Full Text] [Related]
10. Treatment with a novel agent combining docosahexaenoate and metformin increases protectin DX and IL-6 production in skeletal muscle and reduces insulin resistance in obese diabetic db/db mice.
Mitchell PL; Nachbar R; Lachance D; St-Pierre P; Trottier J; Barbier O; Marette A
Diabetes Obes Metab; 2017 Mar; 19(3):313-319. PubMed ID: 27800648
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration.
Chintoh AF; Mann SW; Lam L; Lam C; Cohn TA; Fletcher PJ; Nobrega JN; Giacca A; Remington G
J Clin Psychopharmacol; 2008 Oct; 28(5):494-9. PubMed ID: 18794643
[TBL] [Abstract][Full Text] [Related]
12. Seven days of euglycemic hyperinsulinemia induces insulin resistance for glucose metabolism but not hypertension, elevated catecholamine levels, or increased sodium retention in conscious normal rats.
Koopmans SJ; Ohman L; Haywood JR; Mandarino LJ; DeFronzo RA
Diabetes; 1997 Oct; 46(10):1572-8. PubMed ID: 9313752
[TBL] [Abstract][Full Text] [Related]
13. Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms.
Cleasby ME; Dzamko N; Hegarty BD; Cooney GJ; Kraegen EW; Ye JM
Diabetes; 2004 Dec; 53(12):3258-66. PubMed ID: 15561958
[TBL] [Abstract][Full Text] [Related]
14. FK-614, a selective peroxisome proliferator-activated receptor gamma agonist, improves peripheral glucose utilization while decreasing hepatic insulin extraction in alloxan-induced diabetic dogs.
Uchino H; Kim T; Lam TK; Yoshii H; Klement P; Williams W; Kawamori R; Giacca A
Metabolism; 2005 Sep; 54(9):1250-8. PubMed ID: 16125538
[TBL] [Abstract][Full Text] [Related]
15. Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats.
Park S; Hong SM; Ahn IL; Kim DS; Kim SH
Neuropsychobiology; 2010; 61(3):148-61. PubMed ID: 20173353
[TBL] [Abstract][Full Text] [Related]
16. Intrahepatic mechanisms underlying the effect of metformin in decreasing basal glucose production in rats fed a high-fat diet.
Mithieux G; Guignot L; Bordet JC; Wiernsperger N
Diabetes; 2002 Jan; 51(1):139-43. PubMed ID: 11756333
[TBL] [Abstract][Full Text] [Related]
17. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
18. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study.
Wu RR; Zhao JP; Guo XF; He YQ; Fang MS; Guo WB; Chen JD; Li LH
Am J Psychiatry; 2008 Mar; 165(3):352-8. PubMed ID: 18245179
[TBL] [Abstract][Full Text] [Related]
19. [Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats].
Chen XP; Yang WY; Bu S; Xiao JZ; Liu XL; Wang N; Zhao WH
Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):280-3. PubMed ID: 15130413
[TBL] [Abstract][Full Text] [Related]
20. Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model.
Chintoh AF; Mann SW; Lam L; Giacca A; Fletcher P; Nobrega J; Remington G
Schizophr Res; 2009 Mar; 108(1-3):127-33. PubMed ID: 19157785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
